设计,合成和结构-活性关系分析二二二松衍生物对抗Osimertinib耐药的NSCLC
Chengliu Jin1, Zhen Zhang1, Peng Liao1
1School of Chemistry and Chemical Engineering, Guangdong Cosmetics Engineering & Technology Research Center, Guangdong Pharmaceutical University Zhongshan 528458 P. R. China.
RSC medicinal chemistry
|November 17, 2025
概括
新的双二氨化合物显示出对EGFR突变的非小细胞肺癌 (NSCLC) 的承诺. 化合物33有效地准了对 osimertinib 耐药的细胞,提供了潜在的新治疗策略.
科学领域:
- 在瘤学瘤学.
- 药用化学 医学化学
- 分子生物学分子生物学
背景情况:
- 非小细胞肺癌 (NSCLC) 是全球癌症死亡的主要原因.
- 表皮生长因子受体 (EGFR) 突变驱动NSCLC,对EGFR氨酸激酶抑制剂 (TKI) 的耐药性限制了治疗疗效.
- 双二胺基基基架已经显示出生物活性,但其衍生物用于治疗EGFR突变的NSCLC,特别是三重突变,尚未得到充分研究.
研究的目的:
- 合成和评估新型二二二胺类同类物作为EGFR突变NSCLC的潜在治疗方法.
- 为了确定有效地对抗耐奥西默提尼布NSCLC细胞系的强效化合物.
- 阐明这些新型化合物的结构-活性关系 (SAR).
主要方法:
- 合成和表征36个双二胺类同类物.
- 对NSCLC细胞系的抗增殖活性评估.
- 结构-活动关系分析侧重于C2和N10替代剂.
- 在体外测试包括殖民地形成,迁移,细胞循环停止,细胞亡诱导和西方抹杀用于信号通路分析.
主要成果:
- 化合物33对H1975TM细胞 (EGFRL858R/T790M/C797S) 显示出显著的抗增殖活性,其IC50 (2.7μM) 比 osimertinib (6.5μM) 低.
- 化合物33抑制了殖民地形成和迁移,诱导了G0/G1细胞周期停止,并在H1975TM细胞中促进了细胞亡.
- 用化合物33的治疗抑制了EGFR和AKT酸化,表明向途径的抑制.
结论:
- 可以优化二二氨框架,以开发强大的分子来对抗耐奥西默提尼布的NSCLC.
- 化合物33是针对复杂EGFR突变的新型NSCLC治疗的有希望的主要候选者.
- 这些发现为未来对抗耐药肺癌的药物开发提供了宝贵的见解.
相关概念视频
Structure-Activity Relationships and Drug Design
1.7K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.7K
Adrenergic Agonists: Chemistry and Structure-Activity Relationship
3.8K
Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
3.8K
Direct-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
2.0K
Cholinergic agonists or cholinomimetics mimic the action of acetylcholine to stimulate the parasympathetic nervous system. They are categorized into direct-acting and indirect-acting agents. The direct-acting cholinergic drugs induce the parasympathetic response by directly binding to the muscarinic or nicotine receptors. In comparison, the indirect-acting cholinergic drugs prevent acetylcholine hydrolysis, indirectly contributing to the extended parasympathetic response.
The direct-acting...
The direct-acting...
2.0K
Cholinergic Antagonists: Chemistry and Structure-Activity Relationship
2.7K
Cholinergic antagonists bind to cholinergic receptors and limit the effects of acetylcholine and other cholinergic agonists. Based on the specific cholinergic receptor affinity, these antagonists are classified as muscarinic or nicotinic. Anticholinergics interrupt parasympathetic innervations while sympathetic innervations remain uninterrupted. Muscarinic antagonists are also called 'muscarinic antagonists', 'antimuscarinics', or 'parasympatholytics'. Nicotinic...
2.7K


